TrialNet Hydroxychloroquine Prevention - The University of Chicago Kovler Diabetes Center

TrialNet Hydroxychloroquine Prevention

April 25, 2019

WRITTEN BY
Karen Wu


 

TOPICS
Type 1 Diabetes TrialNet

TrialNet Hydroxychloroquine Prevention

TrialNet Hydroxychloroquine Prevention

About this Study

TrialNet Hydroxychloroquine (HCQ) Prevention is a double-blinded, multicenter, randomized, placebo-controlled trial to determine whether treatment of participants with Stage 1 T1D (2 or more antibodies with normal glucose tolerance) with HCQ results in delay or prevention of progression to Stage 2 T1D (abnormal OGTT) or Stage 3 T1D (clinical onset).  In this study, 2 out of 3 people will receive active treatment, and others will be given an inactive treatment (placebo).  The drug is a capsule that has to be taken orally daily.

 

Eligibility Criteria

 

What will I be asked to do?

If you join this study, you will visit a TrialNet site to do a screening to see if you meet eligibility. If you meet eligibility, you will return to the site to receive the first dose of the drug and be dispensed enough medication to take at home orally on a daily basis.

Below is a visit outline:

  • Screening Visit
  • Baseline Visit (1stdose given)
  • Month 3 Visit
  • Month 6 Visit (then every 6 months thereafter)

You will also be getting an eye exam at the baseline visit and once a year thereafter.

While the study is going on, neither you nor your study team will know if you’re receiving the drug or the placebo. At the end of the study, we will tell you which group you were in.

As a research volunteer, you can decide to stop being in this study at any time. We hope you will stay in the study. You will be helping us learn how to help people at risk for type 1 diabetes.

How to participate

If you have questions about the study or are interested in participating, please contact Rabia at rali7@uchicago.edu.